By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Rheonix today said that it intends to file for US Food and Drug Administration clearance for its warfarin sensitivity test on its CARD platform.

The Ithaca, NY-based startup said that it intends to file a 510(k) application for the test, which detects three SNPs — VKOR1, CYP2C9*2, and CYP2C9*3 — associated with warfarin sensitivity.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

An Australian study of personalized medicine has run into problems as it recruits patients.

In Science this week: mtDNA analysis give glimpse into decline of Neanderthals in Europe, and more.

The University of Arizona's Raina Maier writes that an understanding of the Earth's microbiome is needed.

The proposed Canadian budget emphasizes partnerships with industry, Nature News reports.

Apr
29
Sponsored by
Covance

This online seminar will review case studies demonstrating the clinical utility of CTCs and cfDNA to define and characterize a variety of dynamic genomic changes throughout the course of cancer detection and treatment.